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OBJECTIVES: This article presents results about risk management indicators per-
formed to HIC (Health Insurance Companies) for CKD (chronic kidney disease) and 
its precursor diseases based on the analysis of large databases achieved through 
the implementation of registry as public policy in Colombia. Also presents the 
economic incentives perceived by them thanks to the good results in risk man-
agement METHODS: CAC (Cuenta de Alto Costo) collects information from HIC in 
Colombia. By law, they report all patients diagnosed with HTA (hypertension),DM 
(diabetes) or CKD in a structure with 81 variables. After the data collection there 
is an audit process and finally, a database of approximately 3.050.000 records is 
obtained which is analyzed and allows the measurement of risk management 
indicators including: early diagnosis of CKD, effectiveness in clinical management, 
progression detention of CKD (less incidence) and calculating the prevalence of 
CKD5. RESULTS: The early diagnosis of CKD is the number of patients with HTA or 
DM studied for CKD corresponding to 38.25 %. The incidence of CKD5 corresponds 
to 11.01 per 100.000 affiliates. The effectiveness in clinical treatment correspond-
ing to the proportion of patient with controlled HTA is 66.54% and finally, the 
calculation of ERC5 prevalence corresponds to 668 ppm. With these results we 
can determine the economic incentives for risk management which is distrib-
uted among the country’s HIC corresponding to USD 44,284,255. CONCLUSIONS: 
Quality record of information as public policy, allows results based evaluation 
which improves attention quality. Of the 52 health insurance companies exist-
ing in Colombia, 25% exceed country risk management goals for all indicators 
and receive a larger sum of money for risk management. Risk management as a 
public policy in Colombia encourages results based competence and contributes 
to achieve savings in the attention of the disease through the implementation of 
nephroprotection programs.
PHS100
WITHDRAWN
PHS101
HeAlTHcARe ReSouRce uSe AmoNg PATIeNTS WITH coNgeSTIve HeART 
fAIluRe IN A lARge HeAlTH oRgANIzATIoN
Bash L.D.1, Weitzman D.2, Sharon O.3, Aviram-Paz M.4, Chodick G.5, Shalev V.2
1Merck and Co., Inc., Rahway, NJ, USA, 2Maccabitech, Maccabi Health Care Services and Tel Aviv 
University, Tel Aviv, Israel, 3MSD Israel, Hod Hasharon, Israel, 4Tel Aviv University, Tel Aviv, Israel, 
5Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel
OBJECTIVES: We characterize healthcare utilization among congestive heart failure 
(CHF) patients in Israel who survived at least a year after diagnosis. METHODS: 
Adult members of a health maintenance organization in Israel (Maccabi Healthcare 
Services, MHS) who were diagnosed with CHF between January 2006 and December 
2012 were assessed. MHS databases are derived from electronic medical records of 
longitudinal data from a stable population of over 2 million and provide compre-
hensive clinical, demographic and health service data. RESULTS: Of 7691 eligible 
patients followed for 3 years after first diagnosis, 6357 (82.6%) survived ≥ 1year 
following diagnosis (mean age 72.7 years (SD 12.3 years)). During the first 6 months 
following diagnosis, these patients had, on average, 11.3 (SD 7.7), 2.8 (SD 3.0) and 
0.11 (SD 0.5) visits to their primary care physician, cardiologist, and nephrologist, 
respectively, and almost 70% had ≥ 1 hospital admission. Healthcare services use 
decreased after the first 6 months. Men were on average younger than women 
(70.2 vs. 76.0 years), had higher rates of cardiovascular comorbidity and saw a car-
diologist more often (p< 0.001) than women. More women had hypertension and 
chronic kidney disease but saw a nephrologist less often (p< 0.001) than men. In 
the first 6 months following diagnosis, women were hospitalized for longer periods 
than men (10.2 (SD 19.8) vs. 9.0 (SD 18.9) mean cumulative days of hospitalization, 
respectively). Similar trends were observed in primary care physician and hospital 
visits between genders. Patients surviving < 1 year from diagnosis tended to use 
outpatient services less often and inpatient services more often than ≥ 1 year sur-
vivors. CONCLUSIONS: Considerable resources are expended on CHF patients, with 
variations between male and female patients. Observations underscore the consid-
erable healthcare burden of CHF patients, apparent even in this Israeli population, 
diagnosis (2003-2011) and months of drug purchases (2010-2011) were compared 
by month of birth. Trends of diagnosis and treatment were determined for the vari-
ous sub-cohorts, and population sector differences were compared. RESULTS: Of 
total population (400,828 children, 51% male), 40467 (10.1%) were diagnosed with 
ADHD and 33188 (8.3%) were treated (usually methylphenidate). Diagnosis levels 
for younger (Y: Aug-Nov) children (10.9%) were lower than older (O: Dec, Jan-March) 
children (9.2%, RR 1.18 CI 1.16 to 1.21). The rate disparity was higher beginning 
school-year (September-December; RR 1.21 CI 1.17-1.26). Any-purchase dispensing 
RR was 1.19 (CI 1.16 to 1.22), while monthly RR was 1.18 (1.17-1.19). RR for dis-
pensing was stable between age-cohorts (1.17-1.22) without trend. Among children 
purchasing drugs, the seasonal variation in drug purchases (adherence) is similar 
Y:O CONCLUSIONS: ADHD diagnosis and medication are common in the primary 
school population. The increased incidence and prevalence among younger children 
in a cohort questions the appropriateness of both diagnosis and medication, sug-
gesting behavioral treatment may often be more suitable to avoid long term costs 
and deleterious effects, than pharmacological intervention.
PHS97
SPecIAlTy PHARmAcy meDIcATIoN comPlIANce AND PeRSISTeNce 
PRogRAm foR PATIeNTS WITH PulmoNARy ARTeRIAl HyPeRTeNSIoN
D’Albini L.1, Tian Y.2, Raspa S.3, Drake W.4
1Accredo, Spring Hill, KS, USA, 2Express Scripts, St. Louis, MO, USA, 3Actelion Pharmaceuticals 
US, Inc., South San Francisco, CA, USA, 4Actelion Pharmaceuticals, US, Inc., South San Francisco, 
CA, USA
OBJECTIVES: Past experience using third party vendors to administer clinical pro-
grams for patients with chronic, progressive conditions resulted in low opt-in rates. 
A direct approach using the Specialty Pharmacy (SP) may have a better opt-in rate 
and compliance and persistence (C&P) with medication regimens. The objective of 
this interventional program administered by a specialty pharmacy (SP) [Accredo 
Specialty Pharmacy, Memphis, TN] was to evaluate a C&P program for bosentan 
(Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) by comparing Pulmonary 
Arterial Hypertension (PAH) patients in the C&P program to a historical control 
group. METHODS: A pharmacist-based C&P program was administered directly 
by the SP that provided the medication and counseling, and patients were initially 
ranked using Morisky medication adherence scale to assess risk of non-adherence. 
Retrospective analysis was performed to measure program opt-in rate and C&P. 
Claims from a historical group (controls) and from the intervention group (cases) 
that received the SP-based C&P program between 04/29/2013 through 11/30/2013 
were analyzed. Claims for naïve users of bosentan were reviewed at 120 days and 
180 days for both persistence (bosentan claims not spaced > 45 days apart) and 
compliance (number of calendar days supplied with bosentan divided by 120 or 
180 days). Early refills were adjusted when considering days covered. Opt-in rates 
were also measured. RESULTS: Opt-in rate for the enhanced SP-based C&P program 
was robust at 97%. No statistically significant difference was seen between the 
control and case groups for persistence or compliance. Use of the Morisky scale 
to drive the number of pharmacist interventions did not impact outcomes in the 
case group. CONCLUSIONS: SP-based programs can achieve high participation that 
may drive medication compliance, which is essential in progressive diseases like 
PAH. Future programs should be SP-based to replicate the high opt-in rate while 
establishing new interventions to drive compliance and persistence.
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OBJECTIVES: Despite significant advancements in antiretroviral therapy (ART), 
long-term consistent adherence to therapy remains a challenge for many persons 
living with HIV (PLWH). Pharmacists are well-positioned to promote adherence 
to ART beyond mandated dispensing services, but face many barriers, including 
non-reimbursement for adherence promotion activities (APA). Our study exam-
ines the extent to which pharmacists’ barriers (e.g., inadequate staff, no space) 
influence the level of APA in different pharmacy settings. METHODS: We test the 
hypothesis that pharmacists with fewer barriers provide fewer APA to PLWH, using 
generalized linear modelling (GLM). We use factor analysis to generate the APA index 
based on 38 APA (e.g., adherence assessment, customized interventions, monitoring 
activities). RESULTS: We surveyed 225 pharmacists from 41 U.S. states: (22% North 
East; 23% Midwest; 28% West; 27% South). The sample was mostly female (63%) 
Caucasian (66%), and > 30 years (67%). Most pharmacists had a HIV certification 
(68%); 31% worked in specialty-only and 21% in traditional-only pharmacies. Only 
26% of pharmacists reported APA-related reimbursements. Despite most pharma-
cists (95%) reporting > 5 barriers, the barriers index odds ratio (OR) was insignificant 
(OR: 1.007; p< .774). Insurance status [public vs. none (OR: 1.76 (p< .002) & private vs. 
none (OR: 1.90 p< .004)], pharmacy type [specialty vs. traditional (OR: 2.24 p< 0.001)] 
and HIV certification vs. none (OR: 3.65; p< .001) were significant predictors of APA. 
Interestingly, the OR of high volume (> 500 scripts/day) was significant only at 10% 
level (OR: 0.73 p< .07). CONCLUSIONS: The choice of pharmacy largely determines 
PLWH access to adherence promotion services from certified pharmacists. Our find-
ing that pharmacies that invest in HIV certification training are more likely to have 
higher levels of APA has implications for third party payers interested in adherence 
promotion as a cost containment strategy. Despite lack of reimbursement for adher-
ence promotion, many pharmacists are providing these important services to PLWH.
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